With budgets tightening and department priorities shifting, now is the time for companies to evaluate outside legal counsel.

Following industry news these days, it’s hard to avoid theories that the economic instability created by COVID-19 will be the death of patent prosecution.

As businesses feel the lingering stress from the COVID-19 pandemic, some are considering bringing patent prosecution in-house in order to cut costs. With clients continuing to mind their budgets, how can firms demonstrate the cost savings and ROI they bring to the table?

Biopharmaceutical companies AbbVie Inc. and Allergan recently announced that they signed a consent decree with the U.S. Federal Trade Commission that will commit the companies to sell some properties if they commence a planned merger.

Big business is all about data. We see it in almost every industry, from healthcare to financial services to aviation and beyond. But the legal industry has been slow to adapt.

Executives at T-Mobile may be weighing a potential merger with Comcast, the largest U.S. cable provider. 

Patents for Humanity is the USPTO awards competition recognizing inventors and innovators who develop game-changing technology to meet global humanitarian challenges. With the application deadline quickly approaching, we take a look at some of the past award recipients and celebrate their impact on society today.

Fiat Chrysler and Peugeot owner PSA Group recently announced the terms of a $48 billion merger that would create the world's fourth-largest automaker. A primary reason for the merger is to share the cost of developing electric and autonomous vehicles.

We often use allowance rate as a quick and simple way to quantify success at the USPTO -- and we know law firms use it too. However, that is just one of many indicators in-house counsel can use to evaluate firm performance. 

Pfizer and Mylan, the maker of EpiPens, are merging. Pfizer will offload Upjohn, its portfolio of drugs that are no longer protected by patents, including Viagra, Lipitor and Celebrex, combining with rival Mylan to create a new company that will have a new, yet-to-be-announced name.